The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An open-label, single-arm, dose escalation and expansion phase 1 study of tebotelimab (MGD013) plus niraparib in patients with locally advanced or metastatic gastric cancer who failed prior treatments.
 
Miaozhen Qiu
No Relationships to Disclose
 
Hongming Pan
No Relationships to Disclose
 
Ka On Lam
No Relationships to Disclose
 
Jufeng Wang
No Relationships to Disclose
 
Yi Zheng
No Relationships to Disclose
 
Huiyan Luo
No Relationships to Disclose
 
Yu Zheng
No Relationships to Disclose
 
Xiaoa Zhen
Employment - Zai Lab
Stock and Other Ownership Interests - Zai Lab
 
Wenzhao Hang
Employment - Zai Lab
Stock and Other Ownership Interests - Zai Lab
 
Jianmei Hou
Employment - Zai Lab
Stock and Other Ownership Interests - Zai Lab
 
Rui-hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; HenRui; Junshi Biosciences; KYM Biosciences; Merck Serono; Roche